Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.64 |
| ▸ | ACE | P12821 | 5/20 | 0.63 |
| ▸ | CPA1 | P15085 | 5/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanyl-Dl-Phenylalanine SCHEMBL27689824 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28142228 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28127119 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL2597740 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL4238049 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL893241 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28743188 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28142226 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL29702065 | 0.97 | MME (0.61) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL10646215 | 0.94 | MME (0.58) | MMECTRB1ACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| US-20260139073-A1 | Antigen Binding Proteins | GLAXO GROUP LIMITED (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | C-BIOMEX CO., LTD. (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4692122-A1 | HUMANIZED ANTIBODIES TARGETING EPHA10 | Korea University Research and Business Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4678240-A2 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | Hangzhou Dac Biotech Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | claimed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| US-20100130416-A1 | MODULATION OF ANGIOGENESIS BY A-BETA PEPTIDE FRAGMENTS | ARCHER PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | claimed |
| US-6429220-B1 | COMPRISES AN ISOTHIAZOLONE COMPOUND AND AN AMINOCARBOXYLIC ACID | KURITA WATER INDUSTRIES LTD. (JP) | 2002-08-06 | — | — | US | claimed |
| US-5374551-A | Measurement of metabolism of alpha-methyl glucoside | BIOLOG, INC. (US) | 1994-12-20 | — | — | US | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | EGFR, ERBB2, IGSF11 | MME 3052/4885CTRB1 3462/4885ACE 4366/4885 |
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | MME 2585/4885CTRB1 1101/4885ACE 4802/4885 |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | H1-10, IGSF11, CD99 | MME 2939/4885CTRB1 4157/4885ACE 4882/4885 |
| US-20100130416-A1 | MODULATION OF ANGIOGENESIS BY A-BETA PEPTIDE FRAGMENTS | VEGFA, APP, IAPP | MME 68/4885CTRB1 1673/4885ACE 596/4885 |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | CA5A, CA1, CA9 | MME 2705/4885CTRB1 2394/4885ACE 2578/4885 |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | MME 1788/4885CTRB1 1842/4885ACE 1098/4885 |
| US-20260139073-A1 | Antigen Binding Proteins | TNFSF11, TNFSF10, CD40 | MME 310/4885CTRB1 4590/4885ACE 4219/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | MME 2476/4885CTRB1 3197/4885ACE 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.